The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma
Official Title: Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5 ug) or Placebo in Prolonging Time to Relapse Following Intended Curative Resection or Percutaneous Ablative Treatment for Hepatocellular Carcinoma
Study ID: NCT00051545
Brief Summary: To evaluate the efficacy of Seocalcitol in prolonging time to relapse following intended curative resection or percutaneous ablative treatment, i.e. percutaneous ethanol injection(s), percutaneous acetic acid injection(s), percutaneous microwave coagulation therapy, or percutaneous radiofrequency ablation for hepatocellular carcinoma (HCC).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
E.g., University Health Network Toronto General Hospital (numerous facilities in Canada are recruiting), Toronto, Ontario, Canada
E.g., Hopital Notre-Dame de Bon Secour, Service de Hepato-gastro-enterologie (numerous facilities are recruiting in France), Metz, , France
E.g., Osp. Maggiore, Policlinico di Milano, Divisione di Medicina Interna (numerous facilities are recruiting in Italy), Milano, , Italy
E.g. Hospital Clinic Provincial de Barcelona (numerous facilities are recruiting in Spain), Barcelona, , Spain
E.g., The University of Edinburgh Royal Infirmary (numerous facilities are recruiting in UK), Edinburgh, , United Kingdom
Name: Hanne Hvidberg, MScPharm PhD
Affiliation: LEO Pharma
Role: STUDY_DIRECTOR